Ca<sup>2+</sup>-Activated K<sup>+</sup> Channel K<sub>Ca</sub>3.1 as a Therapeutic Target for Immune Disorders

DOI Web Site Web Site PubMed 6 Citations 64 References Open Access
  • Ohya Susumu
    Department of Pharmacology, Graduate School of Medical Sciences, Nagoya City University
  • Kito Hiroaki
    Department of Pharmacology, Graduate School of Medical Sciences, Nagoya City University

Bibliographic Information

Other Title
  • Ca²⁺-Activated K⁺ Channel K[Ca]3.1 as a Therapeutic Target for Immune Disorders

Search this article

Abstract

<p>In lymphoid and myeloid cells, membrane hyperpolarization by the opening of K+ channels increases the activity of Ca2+ release-activated Ca2+ (CRAC) channels and transient receptor potential (TRP) Ca2+ channels. The intermediate-conductance Ca2+-activated K+ channel KCa3.1 plays an important role in cell proliferation, differentiation, migration, and cytokine production in innate and adaptive immune systems. KCa3.1 is therefore an attractive therapeutic target for allergic, inflammatory, and autoimmune disorders. In the past several years, studies have provided new insights into 1) KCa3.1 pharmacology and its auxiliary regulators; 2) post-transcriptional and proteasomal regulation of KCa3.1; 3) KCa3.1 as a regulator of immune cell migration, cytokine production, and phenotypic polarization; 4) the role of KCa3.1 in the phosphorylation and nuclear translocation of Smad2/3; and 5) KCa3.1 as a therapeutic target for cancer immunotherapy. In this review, we have assembled a comprehensive overview of current research on the physiological and pathophysiological significance of KCa3.1 in the immune system.</p>

Journal

Citations (6)*help

See more

References(64)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top